五星体育直播

五星体育直播 Appoints Cynthia Collins to Board of Directors

REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- 五星体育直播 (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced聽the appointment of Cynthia Collins to the Company鈥檚 Board of Directors.

鈥淚 am thrilled to welcome Cindy to our Board,鈥� said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at 五星体育直播. 鈥淪he has been at the forefront of innovation across multiple therapeutic modalities and brings a wealth of knowledge about the CDMO landscape. I look forward to her valuable guidance as we continue expanding the commercial footprint of our ECO Synthesis toolbox.鈥�

Ms. Collins added, 鈥淲e have only scratched the surface of what is possible with RNA-based therapeutics, and 五星体育直播鈥� exciting technology is positioned to unlock the promise of this growing field. I have been impressed with the Company鈥檚 progress to date and am delighted to join the Board as we approach multiple exciting milestones in 2025 and beyond.鈥�

Cynthia Collins is a recognized leader with more than four decades of experience working in the pharmaceutical and biotech industry. She currently serves as Executive Chair and interim CEO of Nutcracker Therapeutics, a contract, research, development and manufacturing organization with a next generation RNA precision manufacturing platform. Previously, she was the CEO of Editas Medicine, a premier CRISPR company where she oversaw the first clinical trial administration of an聽in vivo聽CRISPR gene editing therapy. Her other notable roles include CEO of Human Longevity, CEO and general manager of various life science businesses at GE Healthcare, CEO of GenVec, group vice president at Beckman Coulter, CEO of Sequoia Pharmaceuticals, and president of oncology at Baxter Healthcare. Ms. Collins also currently serves as a board member at Certara, MaxCyte, DermTech, Alanis Therapeutics, Draper Laboratories, and Foundation for mRNA Medicines. She holds a bachelor鈥檚 degree in microbiology from the University of Illinois Urbana-Champaign and an MBA from the University of Chicago Booth School of Business.

About 五星体育直播

五星体育直播 is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver庐聽technology platform to discover, develop and enhance novel, high-performance enzymes. 五星体育直播 enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis鈩� manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. 五星体育直播鈥� unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit聽.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as 鈥渁im,鈥� 鈥渁nticipate,鈥� 鈥渁ssume,鈥� 鈥渂elieve,鈥� 鈥渃ontemplate,鈥� 鈥渃ontinue,鈥� 鈥渃ould,鈥� 鈥渄esign,鈥� 鈥渄ue,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥済oal,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渙bjective,鈥� 鈥減lan,鈥� 鈥減ositioned,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥渟eek,鈥� 鈥渟hould,鈥� 鈥渟uggest,鈥� 鈥渢arget,鈥� 鈥渙n track,鈥� 鈥渨ill,鈥� 鈥渨ould鈥� and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management, including but not limited to statements regarding the potential of the ECO Synthesis鈩� platform, and it providing an opportunity for 五星体育直播 to efficiently capture meaningful market share; expectations regarding 五星体育直播 meeting its technical and commercial milestones regarding the ECO Synthesis鈩� platform; and expectations regarding the potential of and future demand for RNAi therapeutics, and whether 五星体育直播 will be able to capitalize on such demand. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond 五星体育直播鈥� control and that could materially affect actual results. Factors that could materially affect actual results include, among others: 五星体育直播鈥� dependence on its licensees and collaborators; if any of its collaborators terminate their development programs under their respective license agreements with 五星体育直播; 五星体育直播 may need additional capital in the future in order to expand its business; if 五星体育直播 is unable to successfully develop and commercialize new technology such as its ECO Synthesis鈩� platform and its dsRNA ligase; 五星体育直播 dependence on a limited number of products and customers, and potential adverse effects to 五星体育直播鈥� business if its customers鈥� products are not received well in the markets; if competitors and potential competitors who have greater resources and experience than 五星体育直播 develop products and technologies that make 五星体育直播鈥� products and technologies obsolete; if 五星体育直播 is unable to accurately forecast financial and operational performance; and market and economic conditions may negatively impact 五星体育直播 business, financial condition and share price. Additional information about factors that could materially affect actual results can be found in 五星体育直播鈥� Annual Report on Form 10-K filed with the Securities and Exchange Commission (鈥淪EC鈥�) on February 27, 2025 and in 五星体育直播鈥� Quarterly Report on Form 10-Q filed with the SEC on October 31, 2024, including under the caption 鈥淩isk Factors,鈥� and in 五星体育直播鈥� other periodic reports filed with the SEC. 五星体育直播 expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

For More Information

Investor Contact
Carrie McKim
(336) 608-9706

Released April 1, 2025